Transcatheter Aortic Valve Replacement for Mixed Aortic Valve Disease: A Propensity Score-Adjusted Analysis From the RISPEVA Registry.

BACKGROUND: The differential outcomes between pure/predominant aortic stenosis (AS) and mixed aortic valve disease (MAVD) in patients undergoing transcatheter aortic valve implantation (TAVI) are still debated. OBJECTIVE: To evaluate the comparative clinical outcomes of patients with MAVD and AS undergoing TAVI using data from the RISPEVA registry. METHODS: A total of 3263 patients were included. Of the 3263 patients, 656 with concomitant moderate/severe aortic regurgitation constituted the MAVD group and 2607 constituted the AS cohort. Primary endpoints were 30-day mortality and 1-year survival. Postprocedural paravalvular regurgitation (PPVR), cerebrovascular events, bleeding, and vascular complications were assessed at 30 days. RESULTS: In the overall population, 30-day mortality in the MAVD group was higher than in AS patients (4.3% vs 2.6%;P=.02); however, no differences were detected after propensity-score matching (4.1% vs 3.5%; P=.62). One-year survival was comparable between MAVD and AS patients in both unmatched and matched cohorts. Left ventricular ejection fraction, pulmonary artery systolic pressure, and PPVR, but not baseline MAVD, were predictors of 30-day mortality. The incidence of PPVR was higher in the MAVD group vs the AS group; this difference was not confirmed in patients implanted with a balloon-expandable device. CONCLUSION: MAVD per se did not negatively affect patients' prognoses, but appears to identify a more complex cohort of patients with a worse clinical and functional status, probably referred to TAVI in a later stage of the disease. Patients with MAVD had a greater propensity to develop PPVR, which is a known predictor of worse outcome; this tendency seems to be mitigated by the implantation of balloon-expandable valves.

First Record of Cenopalpus wainsteini [Trombidiformes: Tetranychoidea: Tenuipalpidae] in the Americas and a Description of the Symptoms It Causes on Pines in Peru.

Cenopalpus wainsteini (Livshitz and Mitrofanov, Proceedings Nikitsky Botanic Garden 39:1-72, 1967), a mite species in the family Tenuipalpidae, was discovered on Pinus sylvestris Thumb. in Lima, Peru, and represents the first record of this species in the Americas. Previously, only Cenopalpus pulcher (Canestrini and Fanzago Acari Academia Cientifico Veneto 5:130-142, 1876) and C. officinalis (Papaioannou-Souliotis, Annals Institut Phytopathology Benaki 15:11-27, 1986) have been reported from the Nearctic and Neotropic regions. The current paper describes and illustrates the morphological characters of female, deutonymph, protonymph and includes the first description of the larval stage of the species. Species of C. wainsteini collected in Peru were compared with specimens collected in Italy, as well as with the original description by Livschitz and Mitrofanov of specimens from Ukraine and the re-description of the species by Arabuli and Kvavadze Int J Acarology 39(7): 538-541 (2013) based on specimens collected in Georgia. Furthermore, notes on Cenopalpus lineola (Canestrini and Fanzago 1876) are included since it is frequently associated with C. wainsteini. Severe damage symptoms caused by this flat mite on its host plants were observed and are discussed herein.

Assessing the Best Prognostic Score for Transcatheter Aortic Valve Implantation (from the RISPEVA Registry).

The ACC/TVT score is a specific predictive model of in-hospital mortality for patients undergoing transcatheter aortic valve implantation (TAVI). The aim of this study was to test its predictive accuracy in comparison with standard surgical risk models (Logistic Euroscore, Euroscore II, and STS-PROM) in the population of TAVI patients included in the multicenter RISPEVA (Registro Italiano GISE sull'impianto di Valvola Aortica Percutanea) registry. The study cohort included 3293 patients who underwent TAVI between 2008 and 2019. The 4 risk scores were calculated for all patients. For all scores, the capability to predict 30-day mortality was assessed by means of several analyses testing calibration and discrimination. The ACC/TVT score showed moderate discrimination, with a C-statistics for 30-day mortality of 0.63, not significantly different from the standard surgical risk models. The ACC/TVT score demonstrated, in contrast, better calibration compared with the other scores, as proved by a greater correspondence between estimated probabilities and the actual observations. However, when the ACC/TVT score was tested in the subgroup of patients treated in a more contemporary period (from 2016 on), it revealed a slight tendency to lose discrimination and to overestimate mortality risk. In conclusion, in comparison with the standard surgical risk models, the ACC/TVT score demonstrated better prediction accuracy for estimation of 30-day mortality in terms of calibration. Nevertheless, its predictive reliability remained suboptimal and tended to worsen in patients treated more recently.